CA3223786A1 - Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application - Google Patents

Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application Download PDF

Info

Publication number
CA3223786A1
CA3223786A1 CA3223786A CA3223786A CA3223786A1 CA 3223786 A1 CA3223786 A1 CA 3223786A1 CA 3223786 A CA3223786 A CA 3223786A CA 3223786 A CA3223786 A CA 3223786A CA 3223786 A1 CA3223786 A1 CA 3223786A1
Authority
CA
Canada
Prior art keywords
group
pyrazol
methyl
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3223786A
Other languages
English (en)
French (fr)
Inventor
Patrick Bernardelli
Stephanie Deprets
Laurent Dubois
John Macor
Frederic Petit
Corinne Terrier
Marc Bianciotto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21315095.6A external-priority patent/EP4105218A1/en
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA3223786A1 publication Critical patent/CA3223786A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CA3223786A 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application Pending CA3223786A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21315095.6 2021-06-15
EP21315095.6A EP4105218A1 (en) 2021-06-15 2021-06-15 Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
EP22315117 2022-06-02
EP22315117.6 2022-06-02
PCT/EP2022/066231 WO2022263472A1 (en) 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Publications (1)

Publication Number Publication Date
CA3223786A1 true CA3223786A1 (en) 2022-12-22

Family

ID=82214141

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3223786A Pending CA3223786A1 (en) 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Country Status (11)

Country Link
US (1) US20240383901A1 (https=)
EP (1) EP4355748A1 (https=)
JP (1) JP2024525150A (https=)
KR (1) KR20240021910A (https=)
AU (1) AU2022294022A1 (https=)
BR (1) BR112023025042A2 (https=)
CA (1) CA3223786A1 (https=)
CO (1) CO2024000083A2 (https=)
IL (1) IL309195A (https=)
MX (1) MX2023015016A (https=)
WO (1) WO2022263472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025141029A1 (en) * 2023-12-27 2025-07-03 Sanofi Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application
KR20250163526A (ko) 2024-05-14 2025-11-21 김성우 음전하 증폭장치가 장착된 어싱용 발판

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
US11214565B2 (en) * 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
EP3587422A4 (en) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
WO2020092136A1 (en) * 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES

Also Published As

Publication number Publication date
KR20240021910A (ko) 2024-02-19
IL309195A (en) 2024-02-01
BR112023025042A2 (pt) 2024-02-27
MX2023015016A (es) 2024-05-31
AU2022294022A1 (en) 2024-02-01
CO2024000083A2 (es) 2024-04-08
EP4355748A1 (en) 2024-04-24
JP2024525150A (ja) 2024-07-10
WO2022263472A1 (en) 2022-12-22
US20240383901A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
AU2020228799B2 (en) JAK inhibitor compound and use thereof
KR101911697B1 (ko) Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
AU2019237992B2 (en) Oxadiazole transient receptor potential channel inhibitors
AU2010249380B2 (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
JP6114313B2 (ja) 含窒素複素環化合物またはその塩
KR102522832B1 (ko) 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 피라졸로［１，５―ａ］피리미딘 유도체
JP2022523981A (ja) 抗癌剤として有用な縮合三環式化合物
AU2018381574B2 (en) Pyrrolo(pyrazolo)pyrimidine derivative as LRRK2 inhibitor
AU2017378943A1 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
KR20180003472A (ko) 카이네이즈 저해제로서의 피라졸로피리미딘 유도체
AU2025226693A1 (en) Monoacylglycerol lipase modulators
MX2014008605A (es) Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
EP2435438A1 (en) Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2011001333A (es) Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
EP2569314A1 (en) Fused bicyclic kinase inhibitors
CA3223786A1 (en) Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application
JP2024512449A (ja) 大環状ｌｒｒｋ２キナーゼ阻害剤
TW202412784A (zh) 氮-喹唑啉化合物及使用方法
IL324884A (en) TREM2 modulators
KR20170094180A (ko) 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 삼환식 피라졸로［１，５―ａ］피리미딘 유도체
EP4105218A1 (en) Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
EP4313293B1 (en) Tetrahydrothieno pyridine derivatives as ddrs inhibitors
ES2771151T3 (es) Derivados de piperidina como inhibidor de señalización wnt
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
EA041259B1 (ru) Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250604

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250604

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250821

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250821

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260401

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260401

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260402

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260402

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260402

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260402

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260402